Abeona Therapeutics Inc. (ABEO) Rating Reiterated by Maxim Group
Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reissued by investment analysts at Maxim Group in a research note issued on Wednesday. They presently have a $14.00 target price on the biopharmaceutical company’s stock. Maxim Group’s target price points to a potential upside of 112.44% from the stock’s previous close.
ABEO has been the topic of a number of other research reports. Cantor Fitzgerald started coverage on Abeona Therapeutics in a research report on Wednesday, September 7th. They issued a “buy” rating and a $21.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a research report on Thursday, October 6th. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 12th. FBR & Co reiterated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Friday, August 26th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a research report on Sunday, August 21st. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $14.50.
Abeona Therapeutics (NASDAQ:ABEO) traded down 0.91% during mid-day trading on Wednesday, hitting $6.53. 81,254 shares of the company were exchanged. The stock’s market cap is $219.05 million. Abeona Therapeutics has a 12-month low of $2.05 and a 12-month high of $7.19. The company has a 50 day moving average of $5.36 and a 200 day moving average of $3.47.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/abeona-therapeutics-inc-abeo-rating-reiterated-by-maxim-group.html
Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, equities research analysts expect that Abeona Therapeutics will post ($0.73) earnings per share for the current fiscal year.
In related news, Director Todd Wider acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The shares were bought at an average cost of $5.48 per share, with a total value of $27,400.00. Following the completion of the purchase, the director now directly owns 75,000 shares in the company, valued at $411,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 13.00% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of ABEO. Royce & Associates LP raised its position in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the period. Finally, Sabby Management LLC raised its position in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the period. 19.95% of the stock is currently owned by institutional investors.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.